Qube Research & Technologies (QRT)
NTLA icon

Qube Research & Technologies (QRT)’s Intellia Therapeutics NTLA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-158,235
Closed -$1.42M – 3934
2025
Q4 		$1.42M Buy
+158,235
New +$2.18M ﹤0.01% 2408
2025
Q2 		– Sell
-49,324
Closed -$351K – 3831
2025
Q1 		$351K Sell
49,324
-432,243
-90% -$4.37M ﹤0.01% 2681
2024
Q4 		$5.62M Buy
481,567
+292,634
+155% +$4.57M 0.01% 1422
2024
Q3 		$3.88M Buy
+188,933
New +$4.36M 0.01% 1509
2024
Q2 		– Sell
-44,588
Closed -$1.23M – 4449
2024
Q1 		$1.23M Sell
44,588
-196,103
-81% -$5.45M ﹤0.01% 2027
2023
Q4 		$7.34M Buy
240,691
+195,432
+432% +$5.62M 0.01% 862
2023
Q3 		$1.43M Sell
45,259
-24,481
-35% -$950K ﹤0.01% 1561
2023
Q2 		$2.84M Buy
69,740
+46,774
+204% +$1.9M 0.01% 905
2023
Q1 		$856K Sell
22,966
-1,869
-8% -$73.3K ﹤0.01% 1355
2022
Q4 		$866K Buy
+24,835
New +$1.18M ﹤0.01% 1283
2022
Q2 		– Sell
-16,572
Closed -$1.2M – 2933
2022
Q1 		$1.2M Buy
+16,572
New +$1.4M 0.01% 1070
2021
Q4 		– Sell
-1,652
Closed -$222K – 2837
2021
Q3 		$222K Sell
1,652
-16,932
-91% -$2.56M ﹤0.01% 1611
2021
Q2 		$3.01M Buy
+18,584
New +$1.45M 0.03% 564

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NTLA Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 158,235 shares — an estimated $1.42M sold.

Qube Research & Technologies (QRT) first reported a position in NTLA in Q2 2021 and held it in 13 quarters. The position peaked at $7.34M in Q4 2023. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 158,235 Intellia Therapeutics shares in Q1 2026, an estimated $1.42M.
  • Qube Research & Technologies (QRT) first reported a position in Intellia Therapeutics in Q2 2021 and held it in 13 quarters.
  • Qube Research & Technologies (QRT)'s Intellia Therapeutics position peaked at $7.34M in Q4 2023.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.